

**22nd Annual John Goldman E-Conference on
Chronic Myeloid Leukemia: Biology and Therapy
October 1-4, 2020**

Chairs: J. Cortes, T.P. Hughes, D.S. Krause
**Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F-X. Mahon, D. Perrotti,
J. Radich, D. Réa**

**Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann,
P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten**

Thursday, October 1, 2020

14:00-14:10	WELCOME	Jorge Cortes (Augusta)
14:10-14:20	iCMLf - A REVIEW	Tim P. Hughes (Adélaïde)
14:20-14:48	SPECIAL INTRODUCTORY LECTURE Chair: Jerry Radich (Seattle)	
14:20-14:23	<i>Introduction</i>	
14:23-14:38	Title: TBA	John Dick (Toronto)
14:38-14:48	<i>Discussion</i>	
14:48-16:40	SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020 Chairs:	
14:48-14:51	<i>Introduction</i>	
14:51-15:03	Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure	Susan Branford (Adelaide)
15:03-15:15	Tgf β r - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment	Bac Viet Le (Warsaw)
15:15-15:27	Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib	Jorge Cortes (Augusta)
15:27-15:39	Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Asciminib or an Asciminib Proteolysis-Targeting Chimera (PROTAC)	Thomas O'Hare (Salt Lake City)

15:39-15:51	Therapeutic Inhibition of Malignant FcγRIIb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia	Mirle Schemionek (Aachen)
15:51-16:03	Molecular Status 36 Months after TKI-Discontinuation in CML Is Highly Predictive for Later Loss of MMR - a Report from after-SKI.	Johan Richter (Lund)
16:03-16:15	Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts	Marta Kolba (Warsaw)
16:15-16:40	<i>Discussion</i>	
16:40-16:50	<i>Break</i>	
16:50-17:18	TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE Chair:	
16:50-16:53	<i>Introduction</i>	
16:53-17:08	Understanding and targeting the stem cell origins of myeloid malignancies	Ulrich Steidl (New York)
17:08-17:18	<i>Discussion</i>	
17:18-19:05	SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONNEMENT Chair: TBA	
17:18-17:21	<i>Introduction</i>	
17:21-17:36	<i>Keynote presentation</i>	TBA (TBA)
17:36-17:46	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
17:46-17:58	The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment	Christina Karantanou (Frankfurt)
17:58-18:10	Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness	Hassan Almasoudi (Glasgow)
18:10-18:22	Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease	Veronika Sexl (Vienna)
18:22-18:34	Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells	Andrew Wu (Vancouver)
18:34-18:46	The Spliceosome: An Another Regulating System of Gene Expression Deregulated in CP-CML CD34+CD15- Cells	Benjamin Lebecque (Clermont-Ferrand)
18:46-19:05	<i>Discussion</i>	

19:05-19:15 **JANET ROWLEY PRIZE PRESENTATION**
Presenter: Rob Welner (Birmingham)
Awardee 2020: Ravi Bhatia (Birmingham)

19:15-19:30 **JANET ROWLEY PRIZE: SPECIAL LECTURE (2)**
Chair: Rob Welner (Birmingham)

Title to be announced

Ravi Bhatia (Birmingham)

19:30-19:40 *Discussion*

Friday, October 2, 2020

11:30-12:15 **SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION**
Chair: TBA

11:30-11:33 *Introduction*

Selected Abstracts

11:33-11:45 Sterile Inflammation in Normal Hematopoiesis and Leukemia Pablo Llavona (Frankfurt)

11:45-11:57 Immunosuppressive Polarization of T Cell Subsets in Spleen
and Bone Marrow of Mice with CML-like Disease Julian Swatler (Warsaw)

11:57-12:15 *Discussion*

12:15-14:00 ***Lunch***

13:00-14:00 **SATELLITE SYMPOSIUM:**
RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?

Chair: Philippe Rousselot (France)

Speakers: Mario Tiribelli (Italy), Jorge Cortes (USA)

This educational symposium is organized and funded by Incyte Biosciences International Sàrl

14:00-15:35 **SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE**
Chair: TBA

14:00-14:03 *Introduction*

14:03-14:18 ***Keynote Presentation*** TBA (TBA)

14:18-14:28 *Discussion*

Selected Abstracts

14:28-14:40 RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia Shady Adnan-Awad (Helsinki)

14:40-14:52 H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast
Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity
and CAN be Therapeutically Targeted Manuela Mancini (Bologna)

14:52-15:04	Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML	Narissa Parry (Glasgow)
15:04-15:16	Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias	Eleonora Mäkelä (Turku)
15:16-15:33	<i>Discussion</i>	
15:35	<i>Biology Posters - Mentored Poster Walk 1</i> Biology Poster Walk Leaders: TBA	

15:35 – 16:35

CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Clinical trial design	Donald Berry (Houston)
New drugs under development	Jorge Cortes (Augusta) and Tim Hughes (Adelaide)
Understanding and analyzing the new ELN recommendations	Andreas Hochhaus (Jena) and Michael Mauro (New York)

16:35-16:45

Convene in the Main Conference Hall

16:45 -18:20

SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES

Chairs:

16:45-16:55	Introductory overview – concepts and challenges	
16:55-17:07	<i>Novel vaccines</i>	David Scheinberg (New York)
17:07-17:19	<i>CAR-T for myeloid malignancies</i>	Saar Gill (Philadelphia)
17:19-17:31	<i>Bi-specific and allogeneic CAR-T</i>	Xianxin Hua (Philadelphia)
17:31-17:43	<i>Checkpoint inhibitors</i>	Justin Kline (Chicago)
17:43-17:55	<i>Bispecific antibodies in leukemia</i>	Roland Walter (Seattle)
17:55-18:20	General Discussion	

18:20-18:48

SPECIAL LECTURE (3):

Chair:

18:20-18:23	<i>Introduction</i>	
18:23-18:38	CML blast crisis and the microenvironment	Tannishtha Reya (San Diego)
18:38-18:48	<i>Discussion</i>	

18:50 – 19:50

CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Hematopoiesis

Timm Schroeder (Basel)

Immunology

Roland Walter (Seattle) and David Scheinberg (New York)

Saturday, October 3, 2020

08:50-10:50

**WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
PROTEOMICS / SECRETOMICS**

Chairs: Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

08:50-08:55

Introduction

TBA

08:55-09:20

Title: TBA

Anthony Whetton (Manchester)

09:20-09:45

MS-proteomics to uncover the complexity
and function of the cell secretome

Sara Zanivan (Glasgow)

09:45-10:10

Title: TBA

Oliver Schilling (Freiburg)

10:10-10:40

Discussion

10:40-10:50

Conclusion

11:00-11:10

JOHN GOLDMAN PRIZE PRESENTATION

Presenter: Hemant Malhotra (Jaipur)

Awardee 2020: Jane Apperley (London)

11:10-11:25

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)

Chair: Hemant Malhotra (Jaipur)

Title to be announced

Jane Apperley (London)

11:25-11:35

Discussion

11:35-12:50

SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES

Chair: TBA

11:35-11:38

Introduction

11:38-11:53

Keynote Presentation

TBA (TBA)

11:53-12:03

Discussion

Selected Abstracts

12:03-12:15

A Novel Oral Demethylating Agent, or-2100, in Combination
with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic
Myeloid Leukemia

Kazuharu Kamachi (Saga)

12:15-12:27

Targeting Integrated Stress Response Combined with Imatinib
As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells

Katarzyna Piwocka (Warsaw)

12:27-12:39	Activity of Vodobotinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib	Jorge Cortes (Augusta)
12:39-12:51	Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study	Sung-Hyun Kim (Busan)
12:51-13:10	<i>Discussion</i>	
13:10-14:50	<i>Lunch</i>	

13:20-14:50 **SATELLITE SYMPOSIUM:
TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES**
Chair: Andreas Hochhaus (Jena)
Speakers: Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris)

This educational symposium is organized and funded by Novartis Oncology

14:50-15:00	<i>Convene in the Main Conference Hall</i>	
15:00-15:10	ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY Presenter:	
15:10-15:20	Awardee 2020: Vaidehi Krishnan (Singapore) High dimensional single-cell analysis to predict TFR at the time of CML diagnosis	
15:20-16:55	SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION Chair: TBA	
15:20-15:23	<i>Introduction</i>	
15:23-15:38	<i>Keynote Presentation</i>	TBA
15:38-15:48	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
15:48-16:00	The rate of <i>BCR-ABL1</i> decline after TKI commencement is a strong predictor of sustained Treatment Free Remission	Naranie Shanmuganathan (Adelaide)
16:00-16:12	High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry	Johan Richter (Lund)
16:12-16:24	Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients	Katia Pagnano (Campinas)
16:24-16:36	Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission	François Guilhot (Poitiers)

16:36-16:55	<i>Discussion</i>	
16:55-17:05	<i>Break</i>	
17:05-18:40	SCIENTIFIC SESSION 7: TREATMENT-FREE REMISSION - PREDICTIVE FACTORS Chair: TBA	
17:05-17:08	<i>Introduction</i>	
17:08-17:23	<i>Keynote Presentation</i>	TBA (TBA)
17:23-17:33	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
17:33-17:45	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation	Dennis Kim (Toronto)
17:45-17:57	Chronic Myeloid Leukemia Patients' Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions	Giora Sharf (Netanya)
17:57-18:09	Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia	Robert Gale (London)
18:09-18:21	Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response	Dennis Kim (Toronto)
18:21-18:33	Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study	Frédéric Millot (Poitiers)
18:33-18:50	<i>Discussion</i>	
18:50-19:20	SPECIAL LECTURE (5): Chair:	
18:50-18:53	<i>Introduction</i>	
18:53-19:08	Human evolutionary genomic medicine	Melissa Ilardo (Salt Lake City)
19:08-19:18	<i>Discussion</i>	

Sunday, October 4, 2020

14:30-16:30	WORKSHOP FOR NON-CLINICAL SCIENTISTS #2 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING Chairs: Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)	
14:30-14:35	Introduction	TBA
14:35-15:00	Long-term single-cell quantification: new tools for old questions	Timm Schroeder (Basel)
15:00-15:25	Computational Pathology: Towards Precision Medicine	Andrew Janowczyk (Cleveland)
15:25-15:50	TBA	
15:50-16:20	Discussion	
16:20-16:30	Conclusion	

15:30-16:30 *Clinical Posters - Mentored Poster Walk 2*
Clinical Poster Walk Leaders: TBA

16:30- 16:58 **SPECIAL LECTURE (6):**
Chair: TBA

16:30-16:33 *Introduction*

16:33-16:48 Single cell RNA sequencing in MPN Bethan Psaila (Oxford)

16:48-16:58 *Discussion*

17:00-18:18 **DEBATE: "SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?"**
Chair:

17:00-17:03 *Introduction*

17:03-17:08 **Voting**

17:08-17:28 Against: Charles Schiffer (Detroit)

17:28-17:48 For: Giuseppe Saglio (Turin)

17:48-18:18 **Voting and Discussion**

18:20-18:30 **iCMLf PRIZE PRESENTATION:**
Presenter: Jerry Radich (Seattle)
Awardee 2020: Sabira Kurtovic (Sarajevo)

18:30-18:45 **iCMLf PRIZE: SPECIAL LECTURE (7)**
Chair: Jerry Radich (Seattle)

CML management in war and peace: lessons that shaped
future approaches

Sabira Kurtovic (Sarajevo)

18:45-18:55	<i>Discussion</i>	
18:55-17:40	SCIENTIFIC SESSION 8: TKI SAFETY Chair: TBA	
18:55-18:58	<i>Introduction</i>	
18:58-19:13	Keynote presentation Novel trial designs	Donald Berry (Houston)
19:13-19:23	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
19:23-19:35	Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints	Lando Janssen (Nijmegen)
19:35-19:47	Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia	James Januzzi (Boston)
19:47-19:59	High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study	Massimo Breccia (Rome)
19:59-20:11	<i>Discussion</i>	
20:15	<i>Meeting Adjourned</i>	